IQVIA™ Real-World Insights Bibliography

Guidelines in Germany Early Benefit Assessment - Which Guidelines are Considerend by Federal Joint Committee for Determing the Appropriate Comparator?
Author(s): Scheler E, Stratil AS, Roxlau T, Bonduelle D
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Guidelines, Health policy,
2018
  L:
A:
German
Review,
  Add to report
 
 
Success Factors for §137h SGB V Assessment of Medical Devices in Germany
Author(s): Bonduelle, Doreen; von Hein, Mirko; Scheler, Elisabeth
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Health policy,
2018
  L:
A:
English
Review,
  Add to report
 
 
Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment
Author(s): Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria
Publication(s): 
Document Type(s): Abstract,
Countries: 
C:
Y:
Health economics, Health policy, Pricing and reimbursement,
2018
  L:
A:
English
Pricing & Reimbursement, Review,
  Add to report
 
 
The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases
Author(s): Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): Abstract,
Countries: Germany,
C:
Y:
Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement,
2018
  L:
A:
English
Cost analysis, Pricing & Reimbursement,
  Add to report
 
 
Off-Label Prescription of Drugs Compared to Prescription After Label Extension in Children for Germany
Author(s): Gohlke A, Kostev K, Kuschel AS
Affiliations(s): IQVIA Commercial GmbH & Co. OHG, Munich, Germany
Publication(s): 
Document Type(s): 
Countries: 
C:
Y:
Health policy, Pediatrics, Regulatory,
2018
  L:
A:
English
Utility analysis,
  Add to report
 
 
Valoración de la innovación, ¿es “el innovómetro” una herramienta útil y su clasificación reproducible?
Author(s): Otermin A, Callejo D, Gasche D, Viayna E, Rubio M, Sumalla M, Solozabal M.
Affiliations(s): HEOR-RWI, IQVIA
Publication(s):  XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018
Document Type(s): Poster,
Countries: Spain,
Click here for the abstract
C:
Y:
Health policy, Pricing and reimbursement,
2018
  L:
A:
Spanish
Pricing & Reimbursement,
  Add to report
 
 
Regional policies impact on biosimilar adoption for autoimmune diseases in Italy
Author(s): Tucci C1, Rova A1, Mantuano M1, Tettamanti A1
Affiliations(s): QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Dermatology, Gastrointestinal disorders, Health policy, Rheumatology,
2017
  L:
A:
English
Literature Review,
  Add to report
 
 
The impact of managed entry agreements on drug time to market in Italy
Author(s): Mantuano M1, Rova A1, Urbinati D1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Regulatory,
2017
  L:
A:
English
Literature Review,
  Add to report
 
 
The impact of biosimilar launch on molecule price and pharmaceutical expense: the case of the insulin glargine in Italy
Author(s): Tucci C1, Cioni L1, Mantuano M1, Tettamanti A1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Diabetes, Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
Drug commercialization before the pricing and reimbursement in Italy: the non negotiated C Class (C-nn)
Author(s): Mantuano M1, Cioni L1
Affiliations(s): 1 QuintilesIMS, Milan, Italy
Publication(s):  ISPOR 20th Annual European Congress, 4-8 November 2017, Glasgow, Scotland
Document Type(s): Poster,
Countries: Italy,
C:
Y:
Health policy, Pricing and reimbursement, Regulatory,
2017
  L:
A:
English
Literature Review, Pricing & Reimbursement, Public Health,
  Add to report
 
 
First Page Previous Page  2 of 12 Next Page Last Page